Dermatologic Therapy最新文献

{"title":"Intralesional 5-Fluorouracil in Nodular Basal Cell Carcinoma: An Exploratory Prospective Pilot Study With 1-Year Follow-Up","authors":"Shatila Torabi,&nbsp;Ahmad Reza Taheri,&nbsp;Monavvar Afzalaghaee,&nbsp;Mahdi El Husseini","doi":"10.1155/dth/9420777","DOIUrl":"https://doi.org/10.1155/dth/9420777","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Surgical excision is the standard for basal cell carcinoma (BCC), but it is frequently unfeasible due to patient comorbidities or sensitive lesion sites. This study evaluates the 1-year efficacy of intralesional 5-fluorouracil (IL 5-FU) for nodular BCC, addressing a critical gap in 1-year follow-up literature. This exploratory pilot study was designed to generate hypotheses regarding the 1-year durability of IL 5-FU and its potential as a neoadjuvant agent.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This prospective, single-arm pilot trial evaluated 12 patients with 23 biopsy-proven nodular BCC lesions. Patients received weekly intralesional injections of 50 mg/mL 5-FU (with lidocaine/epinephrine) for 6–10 weeks. Primary outcomes included relative reduction in two-dimensional surface area and complete clinical response (CCR) at 6 months and 1 year.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>IL 5-FU demonstrated a profound debulking effect, reducing mean two-dimensional lesion surface area by 84.22%. The CCR rate was 65.2% (15/23 lesions) at 6 months but declined to 52.17% (12/23 lesions) at 1 year due to three delayed clinical recurrences; notably, because post-treatment biopsies were limited to clinically suspicious lesions, this rate may overestimate the true histopathologic cure by missing occult microscopic disease. At the patient level (<i>n</i> = 12), only 33.3% (4 of 12) achieved a sustained CCR across all treated lesions at the 1-year mark. The treatment was well-tolerated with zero reported pain in the immediate postprocedure period and only transient local reactions.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>A 1-year CCR rate of 52.17% is insufficient to universally replace surgical excision. However, the true value of IL 5-FU appears to lie in its remarkable 84.22% debulking capability. This observed debulking effect supports prospective evaluation of a potential neoadjuvant role to downstage large or anatomically complex tumors before tissue-sparing surgery.</p>\u0000 \u0000 <p><b>Trial Registration:</b> IRCT20240822062839N1.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/9420777","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149146828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Marine-Derived Biomaterials in Psoriasis Treatment: Therapeutic Potential and Development Perspectives","authors":"Tri Purwa Ningrum,&nbsp;Nguyen Vu Linh,&nbsp;Fazlurrahman Khan,&nbsp;Young-Mog Kim,&nbsp;Hyun-Woo Kim,&nbsp;Jae-Young Je,&nbsp;Woo-Ram Um,&nbsp;Won Sun Park,&nbsp;Tae-Hee Kim,&nbsp;Won-Kyo Jung","doi":"10.1155/dth/7466765","DOIUrl":"https://doi.org/10.1155/dth/7466765","url":null,"abstract":"<p>Psoriasis is a multifactorial skin disease characterized by inflamed, scaly lesions arising from abnormal keratinocytes proliferation and immune dysregulation. Its persistent and relapsing nature underscores the need for long-term treatment, making natural products increasingly attractive as alternative therapeutic options. While research has predominantly focused on plant-based sources, marine-derived biomaterials represent untapped yet promising source of bioactive compounds. This review highlights the therapeutic potential of marine-derived biomaterials, whose anti-inflammatory and immunomodulatory properties are key features desirable in effective psoriasis treatments. By shedding light on these promising marine resources, this paper proposes a new direction for the development of safer, more sustainable, and innovative therapies for psoriasis management.</p>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/7466765","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149146911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Selumetinib-Induced Acneiform Eruption: Systematic Review and Proposed Therapeutic Algorithm","authors":"Elisa Marzola,&nbsp;Federico Gianessi,&nbsp;Mattia Minghini,&nbsp;Edoardo Arlotti,&nbsp;Alessandro Borghi","doi":"10.1155/dth/3995242","DOIUrl":"https://doi.org/10.1155/dth/3995242","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Selumetinib, a MEK1/2 inhibitor approved for symptomatic, inoperable plexiform neurofibromas in neurofibromatosis type 1, is frequently associated with skin adverse events, including acneiform eruptions.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A systematic review was conducted in accordance with PRISMA 2020 guidelines in order to explore selumetinib-associated acneiform eruptions. A comprehensive literature search was performed in PubMed, Embase, and Scopus databases. Eligible studies included clinical trials, observational studies, and case reports/series. Two independent reviewers screened titles/abstracts and full texts. Data on patient characteristics, incidence, clinical features, and management were extracted and synthesized.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Sixteen studies and an additional unpublished case from the Dermatology Unit of Ferrara, Italy, were included, with 248 cases of selumetinib-associated acneiform eruption among 422 treated patients (58.8%). Lesions mainly involved the face and upper trunk, were typically papulopustular and monomorphic, and usually lacked comedones. Onset was generally early, often within 2 weeks. Management was heterogeneous, but topical agents and oral tetracyclines were the main treatments. Greater severity was associated with systemic antibiotic use. Selumetinib was maintained in most evaluable cases.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Acneiform eruption is a common and clinically relevant selumetinib toxicity. Early recognition and stepwise dermatologic management usually allow symptom control without treatment discontinuation.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/3995242","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149146873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of the Efficacy of Nanofat Grafting With Microneedling in the Treatment of Striae Distensae: A Pilot, Randomized, Controlled, Investigator-Blind Clinical Trial","authors":"Mozhdeh Sepaskhakh,&nbsp;Marzie Rasafian,&nbsp;Soheila Khodakarim,&nbsp;Negin Fazelzadeh Haghighi","doi":"10.1155/dth/8157922","DOIUrl":"https://doi.org/10.1155/dth/8157922","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Background&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Striae distensae (SD) are a common cosmetic concern for many patients. So far, there is no definitive and markedly effective treatment for SD. Considering the histological similarities of SD and scars, and the effectiveness of nanofat in scar treatment, nanofat could be a potential treatment of SD.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Objectives&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;To assess the effect of nanofat in the treatment of SD.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;In this randomized, investigator-blinded, intrapatient split-body clinical trial, patients with bilateral SD received a single session of nanofat grafting on one side of the body and three monthly sessions of microneedling on the contralateral side. Participants were evaluated at baseline and at months 1, 2, and 5 after the initial treatment session for Global Aesthetic Improvement Scale (GAIS), texture improvement, striae width, patient satisfaction, pain severity, and adverse events.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Twenty patients completed the study. Both nanofat and microneedling gradually improved the aesthetic appearance of the striae lesions over treatment sessions (&lt;i&gt;p&lt;/i&gt; &lt; 0.001). At follow-up, more nanofat-treated lesions were rated as “very much improved” than microneedling-treated lesions, although the between-group difference was not statistically significant (&lt;i&gt;p&lt;/i&gt; = 0.242). The texture of striae gradually improved by both treatment regimens (&lt;i&gt;p&lt;/i&gt; &lt; 0.001); nevertheless, the effects of treatments were not statistically different (&lt;i&gt;p&lt;/i&gt; = 0.39). Also, treatments gradually improved striae width during treatment sessions (&lt;i&gt;p&lt;/i&gt; &lt; 0.001), but the effectiveness of treatments was not significantly different (&lt;i&gt;p&lt;/i&gt; = 0.16). Post-inflammatory hyperpigmentation (PIH) developed in 40% of microneedling-treated patients, but none of the nanofat-treated striae cases (0%) developed PIH (&lt;i&gt;p&lt;/i&gt; = 0.003). Patient satisfaction was not significantly different between groups (&lt;i&gt;p&lt;/i&gt; = 0.77).&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusion&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;In this pilot study, nanofat grafting and microneedling produced comparable improvement in SD, with no significant differences in the main efficacy outcomes. The lower PIH incidence with nanofat should be interpreted cautiously. Larger adequately powered trials are needed to confirm these preliminary findings.&lt;/p&gt;\u0000 \u0000 &lt;p&gt;&lt;b&gt;Trial Registration:&lt;/b&gt; Iranian Registry of Clinical Tr","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/8157922","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149146813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Proof of Concept: Home Self-Monitoring of Atopic Skin State Toward Better Emollient Compliance","authors":"J. Le Digabel,&nbsp;C. Lauze,&nbsp;J. Filiol,&nbsp;R. Marinescu,&nbsp;S. Alvarez-Georges,&nbsp;V. Mengeaud,&nbsp;G. Josse","doi":"10.1155/dth/3345481","DOIUrl":"https://doi.org/10.1155/dth/3345481","url":null,"abstract":"<p>Atopic dermatitis (AD) is a high-burden disease for patients. Regular application of emollients is a prophylactic measure for maintaining a more functional skin barrier. The present study aimed at evaluating if home self-monitoring of skin barrier function by the patients themselves could lead to better compliance with emollient application and, as a result, a better skin barrier. Specifically, we aimed to assess patient autonomy in using a connected device for skin barrier measurement and the effectiveness of a personalized emollient application scheme. We conducted two studies. The first study (<i>N</i> = 12 over 4 months) tested patient autonomy in using a connected device for skin barrier measurement and evaluated the kinetics of barrier function during flares. The second study was a proof of concept (<i>N</i> = 8 over 4 months) for evaluating if a dynamic personalized scheme of emollient applications based on the skin condition measurement could improve compliance and skin condition over time. In the first study, patients easily performed skin barrier measurements at home, with skin barrier modifications observed 5 days before a flare. In the second study, patients applied more emollient and maintained a better skin barrier when guided by the personalized application scheme. The proposed approach based on home self-monitoring of the AD skin barrier associated with a personalized and dynamic scheme of emollient application appears promising for better emollient compliance and for maintaining a better skin barrier over long periods. This approach could potentially be integrated into clinical practice to enhance patient outcomes.</p><p><b>Trial Registration:</b> ClinicalTrials.gov identifier: NCT05639738</p>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/3345481","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149146969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advances in Teledermatology for Contact Dermatitis: A Review of Current Evidence and Future Perspectives","authors":"S. Yasamin Parvar,&nbsp;Fateme Khosravi,&nbsp;Khatere Roozbehi,&nbsp;Alireza Amirian,&nbsp;Nessa Aghazadeh Mohandesi,&nbsp;Howard Maibach","doi":"10.1155/dth/5170301","DOIUrl":"https://doi.org/10.1155/dth/5170301","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Teledermatology offers an alternative approach in which patients can be assessed remotely using clinical history and images of skin lesions transmitted through different digital platforms. Suspected allergic contact dermatitis may ultimately require in-person patch testing, while long wait times and limited access to dermatologists can delay evaluation. This review evaluates the current evidence on the use of teledermatology for the remote assessment and management of contact dermatitis (CD).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Method</h3>\u0000 \u0000 <p>Following PRISMA guidelines, we comprehensively searched PubMed, EMBASE, Scopus, and Web of Science libraries for original studies focused on the use of different kinds of teledermatology in the management of CD. Two reviewers independently screened potential studies and extracted data. Risk of bias was assessed using the Newcastle–Ottawa scale.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The review included 20 observational studies, encompassing 39,892 participants, predominantly female and pediatrics with 767 confirmed cases of CD identified through teledermatology, primarily during initial dermatologic assessment without patch testing as a reference standard. Diagnostic agreement ranged from 25% to 94.4%. Patient satisfaction was generally high, with 97.5% parental receptiveness, though concerns about equity and technological access were noted. Teledermatology also proved cost-effective, with studies showing a reduction in unnecessary visits by up to 71% and a quicker consultation response time, often within 24 h.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Teledermatology has shown significant promise in improving access to care and diagnostic accuracy by reducing waiting times and the need for face-to-face consultations in managing CD, particularly for populations facing barriers to traditional face-to-face consultations. Future research should prioritize long-term evaluations and ensure the generalizability of these systems across diverse nationalities and education levels to further enhance their effectiveness in the comprehensive management of CD.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/5170301","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149146968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combined Topical Ruxolitinib and Oral JAK Inhibitors for Nonsegmental Vitiligo: An Exploratory Real-World Case Series","authors":"Fanny Gomarjoyo,&nbsp;Yanhua Liang","doi":"10.1155/dth/6799330","DOIUrl":"https://doi.org/10.1155/dth/6799330","url":null,"abstract":"<p>Topical ruxolitinib and oral Janus kinase (JAK) inhibitors are each effective for nonsegmental vitiligo (NSV), and recent studies have demonstrated the efficacy of specific oral JAK inhibitor–ruxolitinib combinations. However, whether dual JAK inhibition, concurrent topical and systemic JAK blockade, produces similar facial repigmentation across multiple oral JAK inhibitors with differing selectivity profiles remains unknown. This exploratory single-center case series evaluated 26 patients with NSV treated with ruxolitinib 1.5% cream combined with one of the six oral JAK inhibitors (upadacitinib, tofacitinib, ivarmacitinib, ritlecitinib, baricitinib, or abrocitinib) between March 2025 and January 2026. Of the 26 patients, 14 attended at least one follow-up visit; 12 were lost to follow-up due to work commitments or inability to continue treatment costs, as oral JAK inhibitors are not covered by health insurance in this setting. At approximately 3 months, individual F-VASI improvement ranged from −28.6% to 100% (median: 50%; F-VASI50 achieved by 4/7 [57%] and F-VASI75 by 2/7 [29%]). Total-body repigmentation was more modest (individual T-VASI improvement range: −6.2% to 63.5%; median: 13.6%). No serious adverse events occurred. These findings provide preliminary real-world evidence that dual JAK inhibition may be associated with facial repigmentation across heterogeneous oral JAK inhibitor combinations. Whether this represents a shared class effect remains a hypothesis requiring prospective confirmation. The high attrition rate (46%) and small sample size are principal limitations.</p>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/6799330","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149146753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Insights on Birch Triterpenes in the Treatment of Inherited Epidermolysis Bullosa: Translating Experience to Practice","authors":"Dimitra Kiritsi,&nbsp;Kossara Drenovska,&nbsp;Mauricio Torres-Pradilla,&nbsp;Gemma Harrison,&nbsp;Remie Chrabieh,&nbsp;Anna E. Martinez,&nbsp;Snejina Vassileva,&nbsp;Andrea Diociaiuti,&nbsp;Amy S. Paller,&nbsp;Anna L. Bruckner,&nbsp;Malobi Ogboli,&nbsp;May El Hachem","doi":"10.1155/dth/3311322","DOIUrl":"https://doi.org/10.1155/dth/3311322","url":null,"abstract":"<p>Epidermolysis bullosa (EB) comprises a heterogeneous group of rare genetic disorders characterized by skin and mucosal fragility, leading to recurrent blistering, chronic wounds, and significant morbidity. Recent advances have led to the approval of several EB-specific wound treatments, allowing patients, caregivers, and healthcare practitioners a broader arsenal to improve disease management and outcomes. This includes birch triterpenes (also known as birch bark extract or Oleogel-S10), a topical gel containing 10% birch triterpene extract combined with sunflower oil. Here, we consolidate the real-world clinical experience from 12 EB specialists who treated over 140 patients with birch triterpenes in centers across Europe and the USA. Experience in patients treated with birch triterpenes spans both pediatric and adult populations diagnosed with junctional EB and dominant/recessive dystrophic EB, and with both acute and chronic wounds. The authors address patient- and wound-specific considerations, treatment application, removal, and duration, as well as integration with other treatments. The authors, in addition, provide actionable guidance for optimizing treatment regimens, managing patient and caregiver expectations, and addressing challenges related to real-world use of birch triterpenes. The importance of patient education and treatment adherence, as well as assessing functional outcomes, such as pain reduction, improved mobility, and quality of life measures in the evaluation of treatment effectiveness, are also discussed. This review seeks to contextualize the evidence derived from clinical trials with the realities of routine clinical practice, equipping healthcare practitioners to provide care that is both evidence-based and attuned to the unique needs of individuals living with EB.</p>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/3311322","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149048570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reactive Oxygen Species—Mediated Signaling Networks in Photoaging: Mechanistic Insights and Antioxidant Strategies","authors":"Yifan He,&nbsp;Zhoufeng Wu,&nbsp;Yinmao Dong,&nbsp;Li Chen,&nbsp;Hong Meng,&nbsp;Xiaozhen Li,&nbsp;Li Lan","doi":"10.1155/dth/4007218","DOIUrl":"https://doi.org/10.1155/dth/4007218","url":null,"abstract":"<p>Photoaging is a chronic oxidative process initiated by reactive oxygen species (ROS) generated through ultraviolet and visible light interactions with cutaneous chromophores. Acting as pivotal mediators, ROS link photon energy to oxidative stress, inflammation, DNA damage, and extracellular-matrix degradation, ultimately driving the structural and functional decline of the skin. This review synthesizes current understanding of six interconnected redox-sensitive signaling networks—MAPK/AP-1, NF-κB, Nrf2/Keap1, p53, NLRP3 inflammasome, and cellular senescence—that collectively determine cellular fate and tissue homeostasis during chronic photo exposure. Imbalance between prooxidant cascades and antioxidant defenses establishes a self-perpetuating cycle of inflammation, collagen fragmentation, and pigmentary alteration that defines the photoaging phenotype. Emerging antioxidant and photoprotective strategies aim to restore redox equilibrium by enhancing endogenous defenses, modulating key signaling nodes, and improving delivery precision through next-generation platforms. Integrating these mechanistic insights into clinical frameworks may transform photoaging management from symptomatic correction to causal prevention, offering a path toward sustained skin health and resilience across diverse populations.</p>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/4007218","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149048150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Timing of Adalimumab Administration and Clinical Outcomes in Hidradenitis Suppurativa: A Real-World Observational Study","authors":"Natale Schettini,&nbsp;Chiara Moltrasio,&nbsp;Federico Gianessi,&nbsp;Carlo Alberto Maronese,&nbsp;Emma Pedarzani,&nbsp;Lucrezia Pacetti,&nbsp;Gianluca Avallone,&nbsp;Giorgia Valpiani,&nbsp;Sofia Fraternale,&nbsp;Angelo Valerio Marzano,&nbsp;Alessandro Borghi","doi":"10.1155/dth/9048026","DOIUrl":"https://doi.org/10.1155/dth/9048026","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Circadian rhythms are known to regulate tissue biology, including immune response activation. Chronotherapeutic approaches have been shown to optimise therapeutic outcomes across various diseases.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>To assess whether the timing of adalimumab administration is associated with therapeutic outcomes in patients with moderate-to-severe hidradenitis suppurativa (HS).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>In this retrospective multicentre study, HS patients treated with adalimumab at outpatient clinics in Ferrara and Milan (Italy) were asked to report their usual time of drug administration. Patients were divided into two cohorts based on administration time, namely between 12:01 a.m. and 12:00 p.m. (midnight-to-noon group), and between 12:01 p.m. and 12:00 a.m. (noon-to-midnight group). Treatment effectiveness outcomes at subsequent control visits (Weeks 4, 24 and 52), drug safety and drug survival were compared between the two groups.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among 99 HS patients (median age 36 years, Q1–Q3 27–51; 53% males) who met the inclusion criteria, 44 (median age 43,5 years, Q1–Q3 32–56.2; 54% males) received adalimumab between midnight-to-noon and 55 (median age 30 years, Q1–Q3 25–44; 52% males) from noon-to-midnight. HS clinical response (HiSCR) showed no significant differences between the groups at each control visit. At Week 52, International Hidradenitis Suppurativa Severity Score System (IHS4)-55 was achieved by 28.9% and 58% of patients in the midnight-to-noon and noon-to-midnight groups, respectively (<i>p</i> &lt; 0.05); however, this unadjusted difference was not confirmed in the adjusted mixed-effects analysis. No differences were observed between the groups in the adalimumab safety profile or in drug survival.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Adalimumab administration timing was not independently associated with therapeutic response, safety or drug survival in patients with HS. The unadjusted difference in IHS4-55 observed at Week 52 should be regarded as exploratory and hypothesis-generating. Prospective studies are needed to determine whether circadian factors may modulate treatment response in HS.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/9048026","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149048244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}